Immune-Onc Therapeutics

Immune-Onc Therapeutics is a promising clinical-stage oncology company with a focus on developing novel biotherapeutics targeting myeloid cell inhibitory receptors. With its headquarters in Palo Alto, California, the company has assembled a diverse team with deep expertise in drug development from leading biotechnology companies. Immune-Onc's differentiated pipeline is centered around targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Currently, the company is actively developing several promising therapeutics, including IO-108, an antagonist antibody targeting LILRB2 for solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 for the treatment of acute myeloid leukemia, chronic myelomonocytic leukemia, and solid tumors. In addition, the company also has other assets in its pipeline, such as IO-106 and IO-312, as well as undisclosed immunology and oncology programs. The latest investment round saw $25.00M Series B from notable investors including BOCOM International, TriWise Capital, Proxima Ventures Ltd, and Qianzhan Investment Management, marking a significant milestone for Immune-Onc's growth and development. For more information, visit www.immune-onc.com.